The use of oral contraceptives is a well-established acquired risk factor for venous
thrombosis. In 1995, a number of epidemiological studies were published which suggested …

Objective: We determined whether reported intake of oral contraceptives is associated with
an acute phase response, since inflammation is important in atherogenesis and may …

Background: Oral contraceptives (OC) containing different types of progestogens induce
different sensitivities to activated protein C (APC) measured with the thrombin generation …

OBJECTIVE: To evaluate the effect of third-generation oral contraceptives on high-sensitivity
C-reactive protein (CRP), homocysteine, and lipids levels in a population of young, fertile …

Background: It takes many years to obtain reliable values for the risk of venous thrombosis of
hormonal contraceptive users from clinical data. Measurement of activated protein C (APC) …

Objectives The risk of venous thromboembolism (VTE) is highest during the initial months of
oral contraceptive (OC) use. We sought to evaluate the extent of hemostatic variable …

Background: Estrogen-containing oral contraceptives (OCPs) increase the risk for
thrombosis 3-4 fold in otherwise healthy young women, although the absolute thrombosis …

Although the use of oral contraceptives has been frequently associated with an increased
risk of thromboembolic events, definitive prothrombotic mechanisms have not so far been …

Background Venous thromboembolism (VTE) is associated with excessive coagulation
activity, which in part can be attributed to activation of contact system. However, the …

Oral contraceptive (OC) use is associated with an increased risk of venous
thromboembolism. Previous data reported higher thrombotic risk in women using third …